Department of Neurosurgery, Qujing First People's Hospital, Kunming Medical University Affiliated Qujing Hospital, Qujing City, China.
Department of Neurosurgery, Qujing First People's Hospital, Kunming Medical University Affiliated Qujing Hospital, Qujing City, China.
World Neurosurg. 2022 Feb;158:226-233. doi: 10.1016/j.wneu.2021.11.129. Epub 2021 Dec 5.
When conservative therapy fails, microvascular decompression (MVD) has been the preferred treatment of primary trigeminal neuralgia (TN). However, the management of recurrent or persistent TN after MVD can often be difficult. The purpose of the present systematic review was to objectively analyze and summarize the reported literature regarding the feasibility of repeat MVD.
We conducted a database search using the MEDLINE and PubMed databases until July 2020. The search terms used for title and abstract screening were as follows: "recurrent trigeminal neuralgia," "persistent trigeminal neuralgia," "repeat microvascular decompression," and "reexploration." The inclusion criteria for the systematic review were as follows: clinical studies (excluding case studies), repeat MVD treatment of TN, and studies that had recorded the pain relief outcomes, operative findings, and complications (if any).
Of the 1771 initial results obtained, we performed a full text screening of 43 studies, and, ultimately, 19 were deemed eligible. A total of 2247 patients had undergone MVD for TN, of whom, 311 had experienced recurrence (13.84%). Of the 311 patients, 178 had undergone repeat MVD. The average pain-free interval was 27.75 months after the first MVD. The effective rate of repeat MVD was 91.66%, and 71.48% of the patients had had obvious compression found at repeat MVD. The postoperative complication rate after repeat MVD was 37.31% and was due to postoperative adhesions around the nerve and nerve injury caused by partial sensory rhizotomy. The most common complication after repeat MVD was facial numbness (21.89%), although the incidence of other complications was <5%.
For patients with recurrent or persistent pain after MVD, the findings from our systematic review support that repeat MVD remains a feasible treatment for recurrent or persistent TN.
当保守治疗失败时,微血管减压术(MVD)已成为原发性三叉神经痛(TN)的首选治疗方法。然而,MVD 后复发性或持续性 TN 的治疗往往较为困难。本系统评价的目的是客观分析和总结关于重复 MVD 的可行性的报告文献。
我们使用 MEDLINE 和 PubMed 数据库进行了数据库搜索,截至 2020 年 7 月。标题和摘要筛选中使用的搜索词如下:“复发性三叉神经痛”、“持续性三叉神经痛”、“重复微血管减压术”和“再探查”。系统评价的纳入标准如下:临床研究(排除病例研究)、TN 的重复 MVD 治疗以及记录疼痛缓解结果、手术发现和并发症(如有)的研究。
在最初获得的 1771 项结果中,我们对 43 项研究进行了全文筛选,最终有 19 项被认为符合条件。共有 2247 例患者因 TN 接受 MVD 治疗,其中 311 例出现复发(13.84%)。在 311 例患者中,178 例接受了重复 MVD。第一次 MVD 后平均无疼痛间隔为 27.75 个月。重复 MVD 的有效率为 91.66%,71.48%的患者在重复 MVD 时发现明显的压迫。重复 MVD 后的术后并发症发生率为 37.31%,这是由于神经周围的术后粘连和部分感觉根切断引起的神经损伤所致。重复 MVD 后最常见的并发症是面部麻木(21.89%),尽管其他并发症的发生率<5%。
对于 MVD 后疼痛复发或持续的患者,本系统评价的结果支持重复 MVD 仍然是复发性或持续性 TN 的可行治疗方法。